Home › Research › Tau biomarkers
Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer's Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers
Gokce M, Velioglu HA, Bektay MY, Guler EM.. Gerontology, 2023-08-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Alzheimer's disease (AD) is one of the pathologies that the scientific world is still desperate for. The aim of this study was the investigation of diazepam binding inhibitor (DBI) as a prognostic factor for AD prognosis. Methods A total of 120 participants were divided into 3 groups.
What this study adds
Evidence grade: Low
The record lists 120 participants. This study compared levels of diazepam binding inhibitor and other biomarkers among newly diagnosed Alzheimer's patients, patients diagnosed five years earlier, and healthy controls. It is a biomarker comparison and does not report any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gokce, M., Velioglu, H. A., Bektay, M. Y., & Guler, E. M. (2023). Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer's Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers. Gerontology. https://doi.org/10.1159/000531849
Vancouver
Gokce M, Velioglu HA, Bektay MY, Guler EM. Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer's Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers. Gerontology. 2023. doi:10.1159/000531849. PMID: 37607528.
BibTeX
@article{gokce2023-37607528,
author = {Gokce, M. and Velioglu, H. A. and Bektay, M. Y. and Guler, E. M.},
title = {{Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer's Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers}},
journal = {Gerontology},
year = {2023},
doi = {10.1159/000531849},
pmid = {37607528},
url = {https://doi.org/10.1159/000531849}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The aim of this study was the investigation of diazepam binding inhibitor (DBI) as a prognostic factor for AD prognosis.
- Methods A total of 120 participants were divided into 3 groups.
- Forty new diagnosed Alzheimer patients (NDG) who have been diagnosed but have not started AD treatment, 40 patients who diagnosed 5 years ago (D5YG), and 40 healthy control groups (CG) were included in the study.
- Levels of DBI, oxidative stress, inflammatory, and neurodegenerative biomarkers were compared between 3 groups.
Why it matters
This study compared levels of diazepam binding inhibitor and other biomarkers among newly diagnosed Alzheimer's patients, patients diagnosed five years earlier, and healthy controls. It is a biomarker comparison and does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants120
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Gerontology) |
| Journal's citation record | 2 / 4 | Gerontology: journal h-index 151 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 120 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 1 / 6 | Cited 0.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Eray Metin Güler: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Istanbul University: institution h-index 441 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37607528) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.